Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh)
Latest Information Update: 26 Sep 2022
At a glance
- Drugs Mercaptamine bitartrate (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms CyNCh
- 25 Aug 2016 Results published in the Gastroenterology
- 16 Nov 2015 Post-hoc analysis data published in a Raptor Pharmaceuticals media release.
- 06 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.